QURE heads into its July 31 earnings window with short interest climbing, borrow conditions loosening, and a Street that remains constructively positioned despite a volatile few weeks.
The clearest tension this week is in short interest. Bears have been rebuilding positions. Short interest climbed 7.3% over the past week to 17.2% of the free float — a meaningful level for a small-cap biotech, representing roughly 10.7 million shares. That said, the month-on-month picture complicates the narrative: SI is still down about 5.3% from where it was thirty days ago, meaning last week's rebuild is a partial reversal of a prior unwind rather than a fresh assault. The short score of 61.3 has been remarkably stable, drifting in a tight band between 59.9 and 61.5 all month, which suggests the bear thesis hasn't sharpened meaningfully — it's been there for a while.
The borrow market tells a different story from the SI headline. Availability is extremely loose at 613%, meaning there are roughly six shares available to borrow for every one already lent out. That's a wide pool. Even at the 52-week tightest point, availability never dropped below 145% — the borrow was never truly stressed. Cost to borrow has also fallen about 29% over the past month to just 0.43%, near the floor of its recent range. Bears can add to positions cheaply and easily. That's not a squeeze setup — it's a well-supplied short.
Options positioning reinforces the bullish lean. The put/call ratio is running at 0.18, close to the 52-week low of 0.12 and well below the year's high of 1.00. Calls outnumber puts by more than five-to-one. The z-score relative to the 20-day mean is barely above zero, so this isn't a new development — options traders have maintained this bullish tilt consistently. Taken together, the positioning picture is an unusual split: short sellers are rebuilding at 17% of float, but the options market looks almost entirely unconcerned.
The Street is broadly bullish. Nine analysts carry buy ratings versus three holds, with a consensus mean price target of $40.54 against a current price of $26.99 — roughly 50% implied upside. The most recent noteworthy move came from Goldman Sachs, which in April raised its target modestly to $10 while holding a Neutral rating — an outlier versus the pack and well below the current price, suggesting a fundamentally different read on the pipeline risk. The bull case centres on AMT-130 for Huntington's disease and its UK regulatory path. The bear case is textbook early-stage biotech: clinical efficacy uncertainty and a cash-burning balance sheet with no near-term revenue. The negative EPS momentum ranks in the bottom quartile of the universe on both 30- and 90-day windows, and the Piotroski F-score has been weak for several months. The short score rank of 22 places QURE in the more-shorted fifth of its peer group.
The insider activity from June 11 warrants a note, though the context matters. Seven directors and the Chief Strategy Officer all sold on the same day at $27.06 — the cluster is striking in size but low in significance, each trade scoring a 1 out of 10 on trade significance. These are likely scheduled plan sales or vesting events rather than discretionary exits. The 90-day net insider balance is actually positive at roughly 85,800 shares worth $2.2 million, so the directional read over a longer window does not support a bearish insider thesis.
Among correlated peers, MIRM gained 6.4% on the week and MNKD added 8.4%, while QURE managed a modest 2% weekly gain before fading 3.2% on Tuesday. The relative underperformance against the stronger names in the peer basket is worth watching as the July 31 earnings date approaches — QURE's last print in early May produced a 10.3% one-day jump, so the market has shown it can move sharply on results.
The July 31 print will be the next real test of whether the bear rebuild at 17% of float is well-founded or vulnerable to another squeeze.
See the live data behind this article on ORTEX.
Open QURE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
